Fig. 6. Immune cell infiltration phenotypes in BRCA1-null and hypermethylated cases.
a PD-L1 scoring of 53 BRCA1 hypermethylated and 25 BRCA1-null SCAN-B cases using the Roche SP-142 antibody that is evaluated in immune cells. To the left, proportion of positive cases (≥1%), to the right distribution of actual PD-L1 scores for the two groups. b Scoring of tumor infiltrating lymphocytes (TILs) in 52 BRCA1 hypermethylated and 24 BRCA1-null SCAN-B cases based on available whole section H&E slides. c Total number of expressed neoantigens per sample as calculated from substitutions by NeoPredPipe36 for BRCA1-null and BRCA1 hypermethylated SCAN-B cases. d Neoantigens as shown in (c), but stratified for sample groups also by PD-L1 IHC status. Four hypermethylated cases did not have available PD-L1 immunohistochemistry data. All p values reported from statistical tests are two-sided. Source data are provided as a Source Data file.